Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
Crystal Lake, Illinois, January 13, 2026 —AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. This milestone underscores Aptar Pharma’s commitment to advancing vaccine delivery technologies and supporting the development of novel immunization strategies. The Phase II study of CVAX-01 is assessing the safety, tolerability and systemic and mucosal immune response of CastleVax’s intranasal COVID-19 vaccine compared to an FDA-approved injectable mRNA vaccine. Around 200 U.S. adults, including high-risk individuals and those over 65, will be followed for six months to evaluate whether nasal delivery can provide strong mucosal immunity.
This collaboration reinforces Aptar’s position as a trusted partner in the evolving landscape of nasal vaccine delivery systems and next-generation vaccines. By leveraging its deep expertise in regulatory pathways, technical support, and innovative device design, Aptar supports pharmaceutical partners in their efforts to accelerate development and bring cutting-edge solutions to market.
Aptar supports customers throughout the nasal drug development journey: from system design and formulation compatibility to clinical trial support and regulatory guidance. Its Pharma Services platform offers expertise in combination products, device/formulation optimization, and critical testing such as extractables and leachables, helping partners manage development risks and support efforts to accelerate time-to-market.
“Our collaboration on CastleVax’s Phase II trial reflects why leading innovators choose Aptar as their trusted partner for next-generation medicine development and advanced drug delivery,” said Alex Theodorakis, President, Aptar Pharma Prescription. “By offering comprehensive regulatory guidance and technical support, we help our customers navigate complexity with confidence and accelerate the delivery of life-changing therapies to patients worldwide.”
